PT  - JOURNAL ARTICLE
AU  - Wessells, K. Ryan
AU  - Arnold, Charles D.
AU  - Stewart, Christine P.
AU  - Prado, Elizabeth L.
AU  - Abbeddou, Souheila
AU  - Adu-Afarwuah, Seth
AU  - Arnold, Benjamin F.
AU  - Ashorn, Per
AU  - Ashorn, Ulla
AU  - Becquey, Elodie
AU  - Brown, Kenneth H.
AU  - Byrd, Kendra A.
AU  - Campbell, Rebecca K.
AU  - Christian, Parul
AU  - Fernald, Lia C.H.
AU  - Fan, Yue-Mei
AU  - Galasso, Emanuela
AU  - Hess, Sonja Y.
AU  - Huybregts, Lieven
AU  - Jorgensen, Josh M.
AU  - Kiprotich, Marion
AU  - Kortekangas, Emma
AU  - Lartey, Anna
AU  - Le Port, Agnes
AU  - Leroy, Jef L.
AU  - Lin, Audrie
AU  - Maleta, Kenneth
AU  - Matias, Susana L.
AU  - Mbuya, Mduduzi NN
AU  - Mridha, Malay K.
AU  - Mutasa, Kuda
AU  - Naser, Abu Mohd.
AU  - Paul, Rina R.
AU  - Okronipa, Harriet
AU  - Ouédraogo, Jean-Bosco
AU  - Pickering, Amy J.
AU  - Rahman, Mahbubur
AU  - Schulze, Kerry
AU  - Smith, Laura E.
AU  - Weber, Ann M.
AU  - Zongrone, Amanda
AU  - Dewey, Kathryn G.
TI  - Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials
AID  - 10.1101/2021.02.08.21251234
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.08.21251234
4099  - http://medrxiv.org/content/early/2021/02/10/2021.02.08.21251234.short
4100  - http://medrxiv.org/content/early/2021/02/10/2021.02.08.21251234.full
AB  - Background Small-quantity lipid-based nutrient supplements (SQ-LNS) have been shown to reduce the prevalence of anemia and iron deficiency among infants and young children, but effects on other micronutrients are less well known. Identifying subgroups who may experience greater benefits from SQ-LNS, or who are more likely to respond to the intervention, may facilitate the development of public health policies and programs.Objective Our objective was to identify study-level and individual-level modifiers of the effect of SQ-LNS on child hematological and micronutrient status outcomes.Methods We conducted a two-stage meta-analysis of individual participant data from 13 randomized controlled trials of SQ-LNS provided to children 6 to 24 months of age in low- and middle-income countries (n = 15,946). Outcomes were hemoglobin (Hb), inflammation-adjusted plasma ferritin, soluble transferrin receptor, zinc, retinol and retinol binding protein (RBP), and erythrocyte zinc protoporphyrin, and respective dichotomous outcomes indicative of anemia and micronutrient deficiency. We generated study-specific estimates of SQ-LNS vs. control, including main effects and subgroup estimates for individual-level effect modifiers, and pooled the estimates using fixed-effects models. We used random effects meta-regression to examine potential study-level effect modifiers.Results Provision of SQ-LNS decreased the prevalence of anemia (Hb < 110 g/L) by 16% (relative reduction), iron deficiency (plasma ferritin < 12 µg/L) by 56% and iron deficiency anemia (IDA; Hb < 110 g/L and plasma ferritin < 12 µg/L) by 64%. We observed positive effects of SQ-LNS on hematological and iron status outcomes within all subgroups of the study-level and individual-level effect modifiers, but effects were larger in certain subgroups. For example, effects of SQ-LNS on anemia and iron status were greater in trials that provided SQ-LNS for > 12 months and provided 9 mg/d vs. < 9 mg iron/d, and among later-born (vs. first-born) children. There was no effect of SQ-LNS on plasma zinc or retinol, but there was a 7% increase in plasma RBP and a 56% reduction in vitamin A deficiency (RBP < 0.70 µmol/L), with little evidence of effect modification by individual-level characteristics.Conclusions SQ-LNS provided to infants and young children 6-24 months of age can substantially reduce the prevalence of anemia, iron deficiency, and IDA across a range of individual, population and study design characteristics. Policy-makers and program planners should consider SQ-LNS within intervention packages to prevent anemia and iron deficiency. This study was registered at www.crd.york.ac.uk/PROSPERO as CRD42020156663.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: KGD, KRW and CDA had financial support from the Bill & Melinda Gates Foundation for the submitted work; KRW and SYH have received research grants from Nutriset, SAS, outside the submitted work; all other co-authors report financial support for the original trials that contributed data to this paper, but not for the work directly related to this analysis; no other relationships or activities that could appear to have influenced the submitted work.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020156663 https://osf.io/ymsfu/ Funding StatementSupported by Bill & Melinda Gates Foundation grant OPP49817 (to KGD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The analyses were approved by the institutional review board of the University of California, Davis (1463609-1). All individual trial protocols were approved by their relevant institutional ethics committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData described in the manuscript, code book, and analytic code will not be made available because they are compiled from 13 different trials, and access is under the control of the investigators of each of those trials.AGPα-1-acid glycoproteinBMIbody-mass indexCRPC-reactive proteinGMRgeometric means ratioHbhemoglobinIPDindividual participant dataLNSlipid-based nutrient supplementMDmean differenceMNmicronutrientMNPmultiple micronutrient powderMQ-LNSmedium-quantity lipid-based nutrient supplementsMUACmid-upper arm circumferencePDprevalence differencepFplasma ferritinPRprevalence ratiopZnplasma zincRBPretinol binding proteinRCTrandomized controlled trialSESsocio-economic statusSQ-LNSsmall-quantity lipid-based nutrient supplementssTfRsoluble transferrin receptorWASHwater sanitation and hygieneWAZweight-for-age z-scoreWLZweight-for-length z-scoreZPPzinc protoporphyrin